Bulletin
Investor Alert

Moderna Inc.

NAS: MRNA

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Moderna Inc.

After Hours

 --Real time quotes

Aug 10, 2020, 6:36 p.m.

MRNA
/zigman2/quotes/205619834/composite

$

72.01

Change

0.00 0.00%

Volume

Volume 69,148

Real time quotes

/zigman2/quotes/205619834/composite

Today's close

$ 74.10

$ 72.01

Change

-2.09 -2.82%

Day low

Day high

$71.41

$75.00

Open

52 week low

52 week high

$12.47

$95.21

Open

Company Description

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therap...

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Valuation

Price to Sales Ratio

107.47

Price to Book Ratio

5.60

Enterprise Value to Sales

91.39

Total Debt to Enterprise Value

0.02

Efficiency

Revenue/Employee

72,541.00

Income Per Employee

-619,302.00

Receivables Turnover

2.57

Total Asset Turnover

0.03

Liquidity

Current Ratio

7.89

Quick Ratio

7.89

Cash Ratio

7.71

Profitability

Operating Margin

-906.38

Pretax Margin

-854.88

Net Margin

-853.73

Return on Assets

-28.95

Return on Equity

-38.00

Return on Total Capital

-37.83

Return on Invested Capital

-35.81

Capital Structure

Total Debt to Total Equity

11.57

Total Debt to Total Capital

10.37

Total Debt to Total Assets

8.55

Long-Term Debt to Equity

11.27

Long-Term Debt to Total Capital

10.10

Officers and Executives

Name Age Officer Since Title
Mr. Stéphane Bancel 46 2011 President, Founding CEO & Director
Dr. Stephen Hoge 43 2013 SVP-Corporate Development & New Drug Concepts
Mr. David W. Meline 61 2020 Chief Financial Officer
Mr. Juan Andres 54 2017 Chief Technical Operations & Quality Officer
Dr. Tal Zaks 54 2015 Chief Medical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
08/06/2020 Stéphane Bancel
Chief Executive Officer; Director 		10,000   Disposition at $75.82 per share. 758,200
08/05/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,000   Gift at $0 per share. 0
08/05/2020 Stéphane Bancel
Chief Executive Officer; Director 		9,000   Disposition at $77.49 per share. 697,410
08/03/2020 Stéphane Bancel
Chief Executive Officer; Director 		8,097   Disposition at $74.89 per share. 606,384
08/03/2020 Stephen Hoge
President 		20,000   Disposition at $74.89 per share. 1,497,800
08/03/2020 Stephen Hoge
President 		10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
08/03/2020 Stephen Hoge
President 		10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
07/31/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,698   Disposition at $77.96 per share. 132,376
07/31/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,308   Disposition at $76.6 per share. 100,192
07/31/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,391   Disposition at $75.37 per share. 104,839
07/31/2020 Stéphane Bancel
Chief Executive Officer; Director 		6,649   Disposition at $74.41 per share. 494,752
07/30/2020 Stéphane Bancel
Chief Executive Officer; Director 		10,000   Disposition at $77.98 per share. 779,800
07/29/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,000   Gift at $0 per share. 0
07/29/2020 Stéphane Bancel
Chief Executive Officer; Director 		9,000   Disposition at $82 per share. 738,000
07/24/2020 Stéphane Bancel
Chief Executive Officer; Director 		3,852   Disposition at $73.14 per share. 281,735
07/24/2020 Stéphane Bancel
Chief Executive Officer; Director 		2,619   Disposition at $72.23 per share. 189,170
07/24/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,925   Disposition at $71.24 per share. 137,137
07/24/2020 Stéphane Bancel
Chief Executive Officer; Director 		600   Disposition at $69.96 per share. 41,976
07/24/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,450   Disposition at $68.81 per share. 99,774
07/24/2020 Stéphane Bancel
Chief Executive Officer; Director 		600   Disposition at $67.78 per share. 40,668
07/24/2020 Stephen Hoge
President 		1,107   Disposition at $73.33 per share. 81,176
07/24/2020 Stephen Hoge
President 		1,638   Disposition at $72.56 per share. 118,853
07/24/2020 Stephen Hoge
President 		1,160   Disposition at $71.35 per share. 82,766
07/24/2020 Stephen Hoge
President 		595   Disposition at $69.33 per share. 41,251
07/24/2020 Stephen Hoge
President 		500   Disposition at $68.19 per share. 34,095
07/24/2020 Stephen Hoge
President 		1,107   Disposition at $73.33 per share. 81,176
07/24/2020 Stephen Hoge
President 		1,638   Disposition at $72.56 per share. 118,853
07/24/2020 Stephen Hoge
President 		1,160   Disposition at $71.35 per share. 82,766
07/24/2020 Stephen Hoge
President 		595   Disposition at $69.33 per share. 41,251
07/24/2020 Stephen Hoge
President 		500   Disposition at $68.19 per share. 34,095
07/23/2020 Stéphane Bancel
Chief Executive Officer; Director 		10,000   Disposition at $82.22 per share. 822,200
07/23/2020 Stephen Hoge
President 		11,000   Disposition at $82.18 per share. 903,980
07/23/2020 Stephen Hoge
President 		1,363   Disposition at $80.7 per share. 109,994
07/23/2020 Stephen Hoge
President 		969   Disposition at $79.94 per share. 77,461
07/23/2020 Stephen Hoge
President 		325   Disposition at $78.52 per share. 25,519
07/23/2020 Stephen Hoge
President 		300   Disposition at $77.25 per share. 23,175
07/23/2020 Stephen Hoge
President 		1,043   Disposition at $75.58 per share. 78,829
07/23/2020 Stephen Hoge
President 		11,000   Disposition at $82.18 per share. 903,980
07/23/2020 Stephen Hoge
President 		1,363   Disposition at $80.7 per share. 109,994
07/23/2020 Stephen Hoge
President 		969   Disposition at $79.94 per share. 77,461
07/23/2020 Stephen Hoge
President 		325   Disposition at $78.52 per share. 25,519
07/23/2020 Stephen Hoge
President 		300   Disposition at $77.25 per share. 23,175
07/23/2020 Stephen Hoge
President 		1,043   Disposition at $75.58 per share. 78,829
07/23/2020 Stephen Hoge
President 		10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
07/23/2020 Stephen Hoge
President 		10,000   Derivative/Non-derivative trans. at $0.99 per share. 9,900
07/22/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,000   Gift at $0 per share. 0
07/22/2020 Stéphane Bancel
Chief Executive Officer; Director 		9,000   Disposition at $79.61 per share. 716,490
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		100   Disposition at $90.58 per share. 9,058
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		200   Disposition at $87.5 per share. 17,500
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		650   Disposition at $86.18 per share. 56,017
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,200   Disposition at $85.33 per share. 102,396
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		550   Disposition at $84.05 per share. 46,227
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,422   Disposition at $82.94 per share. 117,940
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,004   Disposition at $82.19 per share. 82,518
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		1,000   Disposition at $80.85 per share. 80,850
07/20/2020 Stéphane Bancel
Chief Executive Officer; Director 		200   Disposition at $79.39 per share. 15,878
07/20/2020 Tal Zaks
Chief Medical Officer 		200   Disposition at $90.64 per share. 18,128
07/20/2020 Tal Zaks
Chief Medical Officer 		400   Disposition at $88.76 per share. 35,504
07/20/2020 Tal Zaks
Chief Medical Officer 		354   Disposition at $87.41 per share. 30,943
07/20/2020 Tal Zaks
Chief Medical Officer 		1,000   Disposition at $86.37 per share. 86,370
07/20/2020 Tal Zaks
Chief Medical Officer 		3,469   Disposition at $85.58 per share. 296,877
07/20/2020 Tal Zaks
Chief Medical Officer 		2,409   Disposition at $84.53 per share. 203,632
07/20/2020 Tal Zaks
Chief Medical Officer 		3,425   Disposition at $83.17 per share. 284,857
07/20/2020 Tal Zaks
Chief Medical Officer 		4,488   Disposition at $82.49 per share. 370,215
07/20/2020 Tal Zaks
Chief Medical Officer 		2,205   Disposition at $81.23 per share. 179,112
07/20/2020 Tal Zaks
Chief Medical Officer 		1,650   Disposition at $80.49 per share. 132,808
07/20/2020 Tal Zaks
Chief Medical Officer 		400   Disposition at $78.77 per share. 31,508
07/20/2020 Tal Zaks
Chief Medical Officer 		10,000   Derivative/Non-derivative trans. at $19.15 per share. 191,500
07/20/2020 Tal Zaks
Chief Medical Officer 		10,000   Derivative/Non-derivative trans. at $20.93 per share. 209,300
/news/latest/company/us/mrna

MarketWatch News on MRNA

  1. After 150 days of the COVID-19 pandemic, here are the best- and worst-performing stocks

    2:09 p.m. Today

    - Philip van Doorn

  6. A Covid Vaccine Could Be Ready Sooner Than You Think

    6:00 a.m. Aug. 7, 2020

    - Bill Alpert

  8. Moderna stock price target raised to $65 from $60 at SVB Leerink

    6:22 a.m. Aug. 6, 2020

    - Tomi Kilgore

  16. Moderna shares up 1.7% premarket

    7:07 a.m. Aug. 5, 2020

    - Ciara Linnane

  17. Moderna ended Q2 with $3.1 bln in cash

    7:07 a.m. Aug. 5, 2020

    - Ciara Linnane

  18. Moderna received about $400 mln of customer deposits for supply of COVID-19 vaccine candidate

    7:07 a.m. Aug. 5, 2020

    - Ciara Linnane

  19. Moderna says Phase 3 study of COVID-19 vaccine candidate on track to complete enrollment in Sept.

    7:04 a.m. Aug. 5, 2020

    - Ciara Linnane

  21. Loading more headlines...
/news/nonmarketwatch/company/us/mrna

Other News on MRNA

  1. Biotech IPOs Beat Record During Pandemic

    5:02 p.m. Today

    - Corrie Driebusch

  2. T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security

    4:39 p.m. Today

    - Seeking Alpha

  3. iBio Is One of the Top Pandemic Opportunities

    2:58 p.m. Today

    - InvestorPlace.com

  4. IPO Update: CureVac Readies Plans For U.S. IPO

    12:44 p.m. Today

    - Seeking Alpha

  5. 5 Stocks in the Spotlight on Trump's Coronavirus Vaccine Optimism

    8:38 a.m. Today

    - Zacks.com

  6. Biotech's Q2:  Lots Of Candidates That May Deliver Alpha

    12:29 p.m. Aug. 9, 2020

    - Seeking Alpha

  7. This Company is the Landlord of Life Sciences

    9:36 a.m. Aug. 7, 2020

    - InvestorPlace.com

  9. Moderna to supply 4.5M COVID-19 vaccine doses to Switzerland

    7:11 a.m. Aug. 7, 2020

    - Seeking Alpha

  10. 10-Q: MODERNA, INC.

    4:46 p.m. Aug. 6, 2020

    - Edgar Online - (EDG = 10Q, 10K)

  11. CureVac Starts U.S. IPO Effort

    4:29 p.m. Aug. 6, 2020

    - Seeking Alpha

  13. 5 Biotech Stocks That Offer Long-Term Growth and Value

    1:51 p.m. Aug. 6, 2020

    - InvestorPlace.com

  15. Beyond Meat Stock Is Vulnerable to an ‘Info War’

    11:05 a.m. Aug. 6, 2020

    - InvestorPlace.com

  16. Moderna (MRNA) Q2 Earnings and Revenues Surpass Estimates

    10:17 a.m. Aug. 6, 2020

    - Zacks.com

  19. It’s Time to Get Serious About Inovio Pharmaceuticals

    8:29 a.m. Aug. 6, 2020

    - InvestorPlace.com

  20. Hold Off Buying The Dip in Pandemic Play Inovio Stock

    1:00 a.m. Aug. 6, 2020

    - InvestorPlace.com

  21. Loading more headlines...

At a Glance

Moderna, Inc.

200 Technology Square

Cambridge, Massachusetts 02139

Phone

1 6177146500

Industry

-

Sector

-

Fiscal Year-end

12/2020

View SEC Filings

Revenue

$60.21M

Net Income

$-514.02M

Employees

830.00

Annual Report for MRNA

/news/pressrelease/company/us/mrna

Press Releases on MRNA

  1. John Lepore Joins Moderna as Senior Vice President, Government Engagement

    4:06 p.m. Today

    - BusinessWire - BZX

  2. New Testing Methods Help Ease Diagnostic Burdens in Healthcare

    9:00 a.m. Today

    - PR Newswire - PRF

  5. Moderna Celebrates Pop in Revenue

    10:00 a.m. Aug. 5, 2020

    - Baystreet.ca

  6. Companies Search for More Efficient Ways to Diagnose Viral Diseases

    9:00 a.m. Aug. 5, 2020

    - PR Newswire - PRF

  7. Most Popular US Robinhood Stocks: $UAL $MRNA $NIO

    7:26 a.m. Aug. 5, 2020

    - The Market Signal

  10. Growing Expectations COVID Vaccine Could Be Ready By End Of Year

    8:47 a.m. Aug. 4, 2020

    - Financial News Media

  11. Growing Expectations COVID Vaccine Could Be Ready By End Of Year

    8:45 a.m. Aug. 4, 2020

    - PR Newswire - PRF

  12. Data Raising Hopes for a Pandemic Treatment in 2020

    12:07 p.m. Aug. 3, 2020

    - Baystreet.ca

  15. Nasdaq 100 Movers: ADP, AMD

    10:23 a.m. July 29, 2020

    - MarketNewsVideo.com

  16. Moderna Loses Key Patent Case

    2:59 a.m. July 29, 2020

    - Baystreet.ca

  18. Nasdaq 100 Movers: NXPI, MRNA

    10:26 a.m. July 28, 2020

    - MarketNewsVideo.com

  19. Nasdaq 100 Movers: ULTA, MRNA

    10:29 a.m. July 27, 2020

    - MarketNewsVideo.com

  21. Loading more headlines...
Trending Tickers
  • /quotes/zigman/17636479/composite VUZI+15.60%
  • /quotes/zigman/237947/composite JCP-5.83%
  • /quotes/zigman/59392505/composite NUGT-2.93%
  • /quotes/zigman/59386294/composite JNUG-5.94%
  • /quotes/zigman/65801738/composite TLT+1.11%
X
Powered by StockTwits
Link to MarketWatch's Slice.